Medicine and Dentistry
Patient
100%
Therapeutic Procedure
49%
Combination Therapy
36%
Inpatient
33%
Non Small Cell Lung Cancer
30%
Malignant Neoplasm
29%
Neoplasm
24%
Disease
22%
Oncology
21%
Overall Survival
20%
Clear Cell Renal Cell Carcinoma
18%
Lung Cancer
18%
Chemotherapy
15%
Gastrointestinal Stromal Tumor
15%
Survival
12%
Analysis
11%
Surgery
11%
Biological Marker
10%
Toxicity
10%
Progression Free Survival
10%
Nivolumab
9%
Immunotherapy
9%
Systemic Therapy
9%
Transitional Cell Carcinoma
9%
Radiation Therapy
9%
Clinical Trial
8%
Cisplatin
8%
Imatinib
7%
Age
7%
Arm
7%
Prostate Cancer
7%
Carboplatin
7%
Soft Tissue Sarcoma
7%
Diagnosis
7%
Cancer
6%
Bladder Cancer
6%
Cells
6%
Targeted Therapy
6%
Follow up
6%
Platinum
6%
Metastatic Carcinoma
6%
Phase II Trials
5%
Adverse Event
5%
Recurrent Disease
5%
Nodular Melanoma
5%
Kidney Metastasis
5%
Muscle Invasive Bladder Cancer
5%
Neoadjuvant Chemotherapy
5%
Paclitaxel
5%
Chemoradiotherapy
5%
Sunitinib
5%
Pembrolizumab
5%
Pancreas Cancer
5%
Evaluation Study
5%
Small Cell Lung Cancer
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
28%
Chemotherapy
24%
Neoplasm
15%
Malignant Neoplasm
14%
Diseases
14%
Overall Survival
13%
Cisplatin
12%
Toxicity
12%
Nivolumab
11%
Survival
10%
Progression Free Survival
9%
Lung Cancer
9%
Gastrointestinal Stromal Tumor
9%
Immunotherapy
9%
Carboplatin
8%
Paclitaxel
8%
Renal Cell Carcinoma
8%
Platinum
8%
Gemcitabine
7%
Imatinib
7%
Solid Malignant Neoplasm
6%
Pembrolizumab
6%
Transitional Cell Carcinoma
6%
Adverse Event
6%
Clinical Trial
5%
Ipilimumab
5%
Drug
5%
Renal Cell Carcinoma
5%
Overall Survival
5%
Docetaxel
5%